Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temsirolimus + interferon alfa
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous (temsirolimus), Subcutaneous (interferon Alfa)
01
Overview
Temsirolimus + interferon alfa is a **combination therapy** investigated for treating advanced or metastatic renal cell carcinoma. **Temsirolimus** is an mTOR (mammalian target of rapamycin) inhibitor that impedes cancer cell growth and proliferation by blocking cell-cycle progression and angiogenesis. **Interferon alfa** is a recombinant human cytokine with immunomodulatory and antiproliferative effects, improving the immune system’s ability to target tumor cells. The combination was studied to enhance antitumor activity by pairing targeted inhibition of mTOR with immune modulation, though phase III data did not show improved survival compared to temsirolimus alone[1][2][3].
- Brand names
- Torisel + interferon alfa
- Other names
- temsirolimus + IFN-αtemsirolimus + IFN
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)FKBP1AmTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on temsirolimus + interferon alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temsirolimus + interferon alfa.